Clinical and Translational Gastroenterology

Advancing Precision in Barrett's Esophagus and Dysplasia Diagnoses: WATS3D Study Demonstrates Exceptional Consensus Among Pathologists

Retrieved on: 
Wednesday, March 6, 2024
Consensus, HGD, Dysplasia, Goldblum, LGD, Cleveland Clinic, Marie Cassidy, CDX, Doctor of Philosophy, Intraepithelial neoplasia, Brigham and Women's Hospital, Barrett's esophagus, Hospital, Diagnosis, Mayo Clinic, Health, Patient, EAC, MPH, Clinical and Translational Gastroenterology, Esophageal cancer, Neoplasm, Yale School of Medicine, Esophagus, Gastroenterology, Tufts Medical Center, Medical imaging

WATS3D Study Demonstrates Exceptional Consensus Among Pathologists.

Key Points: 
  • WATS3D Study Demonstrates Exceptional Consensus Among Pathologists.
  • This was a collaborative study among gastrointestinal pathologists who have an interest and expertise in Barrett's esophagus.
  • The pathologists were then asked to evaluate digital images from 60 WATS3D cases with BE.
  • "The significant variability among pathologists assessing Barrett's esophagus poses challenges for accurate diagnosis and treatment decisions, complicating patient care."

Biomerica Reports Fiscal 2023 Year End Results

Retrieved on: 
Friday, August 25, 2023
SAB, Migraine, Osteoarthritis, Helicobacter pylori, LDT, Mayo Clinic, CRC, Hereditary diffuse gastric cancer, The American Journal of Gastroenterology, Intellectual property, EZ, Clinical and Translational Gastroenterology, COVID-19, CVS, Coronavirus Scientific Advisory Board, Completeness, Large intestine, Ulcerative colitis, Gastroesophageal reflux disease, Colorectal cancer, CLIA, American Journal, Phlebotomy, Patient, Physician, IBS, National accounts, Rome, FDA, Stomach, Pharmaceutical industry, Walmart, Gastroenterology

Net sales for the fiscal year ended May 31, 2023 were $5.3 million as compared to net sales of $18.9 million in fiscal 2022.

Key Points: 
  • Net sales for the fiscal year ended May 31, 2023 were $5.3 million as compared to net sales of $18.9 million in fiscal 2022.
  • Net loss was $7.1 million for fiscal 2023 compared to a net loss of $4.6 million for fiscal 2022.
  • The decrease in sales for fiscal 2023 was related to the Company’s decrease in sales of COVID-19 antigen tests in fiscal 2023 compared to the prior fiscal year.
  • Sales revenues excluding Covid test sales increased by 15% for fiscal 2023 compared to fiscal 2022.

EQS-News: Abivax reports 2022 financial results and operations update

Retrieved on: 
Wednesday, April 19, 2023
Operating cost, CD, US Foods, Marketing, United European Gastroenterology, G&A, Malignancy, Congress, COVID-19, Investment, Patient, Ageing, ITT, ARD, HCC, Rheumatoid arthritis, Maintenance, Sofinnova, Neurotransmission, Clinical and Translational Gastroenterology, Methotrexate, De novo, EMA, Cancer, CTG, EULAR, Mall of America, FDA, Natural killer T cell, Safety, European Medicines Agency, Volunteering, Inflammatory Bowel Diseases, PIP, UEG, Ulcerative colitis, Publication, Blood, MTX, Nivolumab, Partnership, RA, ACR20, IBD, Bank statement, ECCO, Bristol Myers Squibb, CCO, Fungal infection, ASCO, EUR, Scripps, Food, Pharmaceutical industry, Management, Abivax, Rheumatology, UC, Gastroenterology

The ABTECT program was initiated in the first half of 2022 and the first patient in the United States was enrolled on October 11, 2022.

Key Points: 
  • The ABTECT program was initiated in the first half of 2022 and the first patient in the United States was enrolled on October 11, 2022.
  • Abivax recently reported the results of its Phase 2b maintenance trial of obefazimod in UC after two years of continued once-daily treatment with 50mg obefazimod.
  • In March 2022, Abivax announced its Phase 2a maintenance trial results of obefazimod in RA.
  • In January 2022, Abivax presented the results of the dose escalation phase of its Phase 1/2 clinical trial in HCC at the ASCO GI Cancers Symposium.

EQS-News: Abivax to present blood and rectal tissue data from UC patients treated with obefazimod at the 18th Congress of ECCO

Retrieved on: 
Wednesday, February 22, 2023
MicroRNA, Ulcerative colitis, Blood, Therapy, Clinical and Translational Gastroenterology, CTG, Maintenance, Patient, Euronext Paris, ECCO, CET, Cytokine, IBD, Congress, Immune system, Poster, Biopsy, Translation, UC, Inflammatory Bowel Diseases, Pharmaceutical industry, Abivax

The abstract is entitled: “Obefazimod upregulates miR-124 and downregulates the expression of some cytokines in blood and rectal biopsies of patients with moderate-to-severe ulcerative colitis.”

Key Points: 
  • The abstract is entitled: “Obefazimod upregulates miR-124 and downregulates the expression of some cytokines in blood and rectal biopsies of patients with moderate-to-severe ulcerative colitis.”
    The Congress of ECCO is one of the world’s leading conferences focused on Inflammatory Bowel Diseases (IBD), such as ulcerative colitis and Crohn’s disease.
  • Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax, said: “After the recent publication of the data in the journal Clinical and Translational Gastroenterology, we are excited by the selection of our abstract for a poster presentation at the ECCO Congress.
  • We believe the blood and biopsy data validates and extends obefazimod’s novel and potent anti-inflammatory mechanism of action.
  • It complements our scientific findings released on our clinical Phase 2a and Phase 2b induction and maintenance results that were generated with obefazimod for the treatment of patients with moderate to severe ulcerative colitis.

Biomerica Appoints Mayo Clinic Gastroenterologist, Dr. Brian E. Lacy, to the Company’s Scientific Advisory Board

Retrieved on: 
Tuesday, January 10, 2023
Gastroesophageal reflux disease, Constipation, United States Air Force Scientific Advisory Board, Indigestion, The American Journal of Gastroenterology, Gastroparesis, Intestinal pseudo-obstruction, Lacy, Rome, Stomach, Mayo Clinic, IBS, Visceral pain, Gastrointestinal tract, Textbook, Patient, Diet, Research, Irritable bowel syndrome, Clinical and Translational Gastroenterology, Science, Book, Dysphagia, Esophageal achalasia, Esophageal motility disorder, Physician, American Journal, Medical device, Pharmaceutical industry, Gastroenterology

Dr. Lacy has authored over 225 peer reviewed articles

Key Points: 
  • Dr. Lacy has authored over 225 peer reviewed articles
    IRVINE, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) appointed prominent physician and key opinion leader Brian E. Lacy, M.D., Ph.D., a board-certified gastroenterologist at Mayo Clinic, to its Scientific Advisory Board which is advising the Company on the commercialization of products based on the Biomerica InFoods® Technology platform, beginning with the InFoods® IBS product.
  • I am honored to provide my expertise to Biomerica along with other esteemed members of the Scientific Advisory Board.”
    Dr. Lacy's areas of expertise include irritable bowel syndrome, gastroesophageal reflux disease, dysphagia, achalasia, dyspepsia, gastroparesis, constipation, intestinal pseudo-obstruction and visceral pain.
  • Additionally, Dr. Lacy was the former co-Editor in Chief of the American Journal of Gastroenterology.
  • “Dr.

EQS-News: Abivax publishes novel data with respect to obefazimod’s anti-inflammatory mechanism of action

Retrieved on: 
Sunday, January 22, 2023
IBD, CET, Clinical and Translational Gastroenterology, Mall of America, IL-6, Euronext Paris, Inflammation, Inflammatory bowel disease, Publication, Patient, Cytokine, CTG, Maintenance, Therapy, MicroRNA, Immune system, Downregulation and upregulation, Ulcerative colitis, IL-17, Pharmaceutical industry, Abivax, UC

It reverses the expression of several inflammatory cytokines without impairing host defense as it does not impact the immune response altogether.

Key Points: 
  • It reverses the expression of several inflammatory cytokines without impairing host defense as it does not impact the immune response altogether.
  • Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax, said: “Abivax feels very encouraged by the data published in our article and the validation and extension of obefazimod’s novel and potent anti-inflammatory mechanism of action.
  • This specific MoA acts through the upregulation of a specific anti-inflammatory microRNA which reduces the expression of several pro-inflammatory cytokines.
  • We believe that obefazimod has the potential to also become an effective long-term therapy for other chronic inflammatory diseases with high medical need.”

PanFAM-1 Results Partly Inconclusive

Retrieved on: 
Monday, June 27, 2022
Patient, Boston University School of Public Health, CEO, Principal investigator, Q&A, COVID, Clinical and Translational Gastroenterology, Industry, CET, Telephone, Cancer, Prevalence, CT, Pancreatic cancer, EUS, Biostatistics, Clinical trial, Observational study, Public health, Webcast, MRI, Observation, Hospital, Medical imaging, Pharmaceutical industry, PDAC

STOCKHOLM, June 27, 2022 /PRNewswire/ -- Immunovia today announced results from the PanFAM-1 study.

Key Points: 
  • STOCKHOLM, June 27, 2022 /PRNewswire/ -- Immunovia today announced results from the PanFAM-1 study.
  • "We aimed for more tangible results of the PanFAM-1 study, which are partly inconclusive due to a variety of factors related to the execution of the clinical trial compared with original study design.
  • Statistical comparison of specific imaging findings and IMMray PanCan-d results is ongoing to examine trends in IMMray PanCan-d results relative to specific germline mutations, family histories, and imaging findings at the direction of the Principal Investigators in this study.
  • Independent analysis of the PanFAM-1 results was conducted by Biostatisticians at the Biostatistical and Epidemiological Data Analysis Center (BEDAC) at Boston University School of Public Health.

Hackensack University Medical Center Offers an Innovative New Screening Option for Patients at High Risk for Pancreatic Cancer

Retrieved on: 
Wednesday, April 27, 2022
Magnet, Hackensack, Adult, High, Sarkis, Hackensack University Medical Center, Patient, Clinical and Translational Gastroenterology, II, Pancreatic cancer, Cancer, U.S. News & World Report, Metabolism, PDAC, Biomarker, Hospital, Multimedia, Interview, Precision medicine, Serum, Risk, EUS, Review, Immunotherapy, CA19-9, Inflammation, News, Disease, Medical imaging, Pharmaceutical industry

The IMMray PanCan-d analyzes 9 biomarkers in serum to detect pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer.

Key Points: 
  • The IMMray PanCan-d analyzes 9 biomarkers in serum to detect pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer.
  • Hackensack University Medical Center, a 771-bed nonprofit teaching and research hospital, is the largest provider of inpatient and outpatient services in New Jersey.
  • Hackensack University Medical Center is also rated as High Performing in 14 specialties procedures and conditions, and sets the standard for all New Jersey hospitals in several specialties.
  • Hackensack University Medical Center's comprehensive clinical research portfolio includes studies focused on precision medicine, translational medicine, immunotherapy, cell therapy, and vaccine development.

IMMray™ PanCan-d - peer-reviewed, blinded validation study now published in Clinical and Translational Gastroenterology

Retrieved on: 
Thursday, February 17, 2022
Gastroenterology, Patient, Clinical and Translational Gastroenterology, Laboratory, PDAC, Cancer, Internet, CA19-9, Medical device

LUND, Sweden, Feb. 17, 2022 /PRNewswire/ -- Immunovia AB (publ) announces that the peer-reviewed, blinded study to independently validate the clinical performance of IMMray™ PanCan-d has been published in Clinical and Translational Gastroenterology. The article is available online on the journal's website. This publication expands on the findings announced on March 29, 2021, and they have now been validated in this peer-reviewed publication. The publication has been authored and reviewed by numerous Key Opinion Leaders in the US and Europe participating in the study.

Key Points: 
  • LUND, Sweden, Feb. 17, 2022 /PRNewswire/ -- Immunovia AB (publ) announces that the peer-reviewed, blinded study to independently validate the clinical performance of IMMray PanCan-d has been published in Clinical and Translational Gastroenterology.
  • The publication has been authored and reviewed by numerous Key Opinion Leaders in the US and Europe participating in the study.
  • Sample collection took place at 11 clinical centers globally and the study was performed by Immunovia, Inc. in Marlborough, MA, USA.
  • I am very pleased that our peer-reviewed validation study results are now publicly available," says Dr. Thomas King, Medical Director, Immunovia.

IMMray™ PanCan-d - peer-reviewed, blinded validation study now published in Clinical and Translational Gastroenterology

Retrieved on: 
Thursday, February 17, 2022
Gastroenterology, Patient, Clinical and Translational Gastroenterology, Laboratory, PDAC, Cancer, Internet, CA19-9, Medical device, Pharmaceutical industry

LUND, Sweden, Feb. 17, 2022 /PRNewswire/ -- Immunovia AB (publ) announces that the peer-reviewed, blinded study to independently validate the clinical performance of IMMray PanCan-d has been published in Clinical and Translational Gastroenterology.

Key Points: 
  • LUND, Sweden, Feb. 17, 2022 /PRNewswire/ -- Immunovia AB (publ) announces that the peer-reviewed, blinded study to independently validate the clinical performance of IMMray PanCan-d has been published in Clinical and Translational Gastroenterology.
  • The publication has been authored and reviewed by numerous Key Opinion Leaders in the US and Europe participating in the study.
  • Sample collection took place at 11 clinical centers globally and the study was performed by Immunovia, Inc. in Marlborough, MA, USA.
  • I am very pleased that our peer-reviewed validation study results are now publicly available," says Dr. Thomas King, Medical Director, Immunovia.